Recomendados
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (20)
Similar a Dkd master class
Similar a Dkd master class (20)
Más de FarragBahbah
Más de FarragBahbah (20)
Último
Último (20)
Dkd master class
- 1. Diabetic Kidney Disease October 2019 Update Hussein Sheashaa, MD, FACP Professor of Nephrology, Urology and Nephrology Center and Director of Medical E- Learning Unit, Mansoura University, ESNT CME Chair and Executive Director of ESNT- Virtual Academy: http://lms.mans.edu.eg/esnt/ Master class, 21 October, 2019
- 3. 1. Epidemiology, presentation and trends 2. Pathology and biomarkers 3. Management 4. Closing Outline
- 4. Kidney International Supplements (March 2019) 9, e1–e81 China Kidney Disease Network (CK-NET)
- 6. Diabetes Care Publish Ahead of Print, published online June 20, 2019 DKD: Albuminuric and Non-albumiuric
- 7. Diabetology International (2019) 10:180–182 CKD with Diabetes
- 8. DKD: Pattern of eGFR Decline Kidney International (2019) 95, 178–187
- 9. Ophthalmic Res, Published online: June 28, 2019 DKD: Role of Fundus Examination
- 10. PLoS One. 2019 Jul 29;14(7):e0220506 DKD: Role of Fundus Examination
- 11. 1. Epidemiology, presentation and trends 2. Pathology and biomarkers 3. Management 4. Closing Outline
- 12. Chronic Renal Disease, Second Edition, 2020, Chapter 19 Diabetic Nephropathy: Overview
- 13. Would You Biopsy Or Not? Case Scenario Am J Kidney Dis. 2019 Jan 17. pii: S0272-6386(18)31102-8.
- 14. Chronic Renal Disease, Second Edition, 2020 Diabetic Nephropathy: Overview
- 15. DM: When To Do Biopsy?
- 16. Acta Diabetol 2019 Aug;56(8):939-946 DM: When To Do Biopsy?
- 17. DKD in Japan: Nonproteinuric (Biopsy) Diabetes Care May 2019;42:891–902 JASN Published online September 05, 2019
- 19. DKD Progression: Total Bilirubin Renal survival rate 7.5 µmol/L = 0.44 mg/dL Endocr Pract. 2019 Jun;25(6):554-561.
- 20. 1. Epidemiology, presentation and trends 2. Pathology and biomarkers 3. Management 4. Closing Outline
- 21. 540 Pages DKD Management: At A Glance
- 22. Use RAAS Blockers for Primary Prevention Am J Kidney Dis. 2019 Jun;73(6):786-796
- 23. Obesity and Diet
- 24. Adipo-Renal Axis: Renal Compression Nat Rev Nephrol. 2019 June;15(6):367-385.
- 26. Diabetic Kidney Disease: Prediabetes Obesity Medicine, Accepted 22 May 2019
- 27. Kidney International (June 2019) 95, 1433–1442 DKD Progression: Role of Diet
- 28. Kidney International (June 2019) 95, 1433–1442 DASH Diet
- 29. Nephrol Dial Transplant (June 2019) 34: 893–896 TMAO, trimethylamine-N-oxide. Diet and CKD: Vegetables in Focus
- 31. www.cjasn.org Vol 14 June, 2019 CJASN ePress. Published on April 17, 2019 DKD: Hypoglycemia
- 33. J Cell Physiol. May 2019; 234: 5786-5797 Anti-diabetic Drugs: Effects on Albuminuria
- 34. DKD: Use of Metformin Diabetes Obes Metab.2019 May;21(5):1199-1208.
- 35. DKD: Use of Metformin Int Urol Nephrol. 2019 Jul;51(7):1229-1230.
- 36. N Engl J Med. 2019 Jun 13;380(24):2295-2306 SGLT2 Inhibitors: CREDENCE Trial Double-blind, randomized trial
- 37. DKD: Renal Congestion Remedy Kidney Blood Press Res August 2019;44:449–456
- 38. Lancet Diabetes Endocrinol. Published online September 5, 2019 SGLT2 Inhibitors for The Prevention of Kidney Failure
- 39. eGFR of more than 30 ml/min per 1.73Nutritional evaluation of elderly? Use of these agents in patients with type 1 DM Kidney International (July 2019) 96, 8–10 DKD: Use of SGLT2I
- 40. Safety of SGLT2 Inhibitors Expert Opin Drug Saf. 2019 Apr;18(4):295-311.
- 41. SGLT2 Inhibitors: EDKA Br J Anaesth. 2019 July;123(1):27-36.
- 42. 13 randomized controlled trials Exp Ther Med. 2019 July;18(1):342-351. GLP1 RA: Liraglutide
- 43. A/Cr UAE Cr Exp Ther Med. 2019 Jul;18(1):342-351. TGFB TNFa IL6 BMI TC TG GLP1 RA: Liraglutide
- 44. GLP1 RA: PIONEER 5 Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527
- 45. Circulation. 2019 Apr 23;139(17):2022-2031 GLP1 RA/SGLT2I
- 46. Circulation. 2019 Apr 23;139(17):2022-2031 Broad Renal OutcomeRenal Outcome excluding macroalbuminuria GLP1 RA/SGLT2I
- 47. JAMA. 2019;321(1):69-79 Double-blind, placebo RCT 605 centers across 27 countries Linagliptin and CV Outcome: (CARMELINA Trial)
- 48. Diabetes, Obesity and Metabolism, Accepted 10 April 2019 DKD: Class Effects
- 49. Medicina (Kaunas). 2019 Jun 11;55(6). pii: E268. Antihyperglycemics in DKD: Management Algorithm
- 50. Other Drugs
- 51. DKD: SONAR Trial Lancet. 2019 May 11;393(10184):1937-1947.
- 52. DKD: Current and Novel Therapies Nat Rev Nephrol. 2019 Feb;15(2):68-70.
- 53. DKD: Anti-ASK1 Selective Inhibitor of Apoptosis signal-regulating kinase 1 JASN 2019 Oct;30(10):1980-1990.
- 54. RRT
- 55. Ren Fail. 2019 Nov;41(1):521-531 HD or PD
- 56. 1. Epidemiology, presentation and trends 2. Pathology and biomarkers 3. Management 4. Closing Outline
- 60. Lessons from Basic Research: Autophagy Dr. Samar Ahmed Mahmoud, MD Nephrology thesis, Mansoura University March 10th, 2019
- 61. Mansoura UNC Stem Cell Research Group
Notas del editor
- Since both retinopathy and nephropathy are major diabetic microvascular complications, we investigated whether severity of diabeticretinopathy (DR) has adverse effects on renal function and albuminuria in the patients with type 2 diabetes mellitus (DM). We screened 2,197 adult patients with type 2 DM who had undergone fundus exam between August 2006 and February 2014. Among them, 1,592 subjects with available serial renal function and albuminuria measurement were included in the analysis. DR status was classified as no DR, non-proliferative DR (NPDR), and proliferative DR (PDR). The risk of CKD progression was assessed according to DR severity. A total of 384 (24.1%) had NPDR and 202 (12.7%) had PDR at either eye. The mean follow-up period was 5.6±2.1 years. DR was associated with lower body mass index, lower plasma hemoglobin, lower serum albumin level, longer duration of DM, poorer control of blood sugar, lower estimated glomerular filtration rate (eGFR), and greater amount of albuminuria. Interestingly, baseline DR severity was associated with faster renal function decline and greater albuminuria progression. In multivariate analysis, NPDR had 2.9 times and PDR had 16.6 times higher risk for CKD progression. Our findings showed that baseline DR severity is a prognostic factor for future CKD progression in type 2 DM patients. Therefore, clinicians must evaluate DR severity at the first visit and closely monitor renal function and albuminuria in the subjects with severe DR.